GB2405336A - Cholinesterase inhibitors to prevent injuries caused by chemicals - Google Patents

Cholinesterase inhibitors to prevent injuries caused by chemicals Download PDF

Info

Publication number
GB2405336A
GB2405336A GB0424188A GB0424188A GB2405336A GB 2405336 A GB2405336 A GB 2405336A GB 0424188 A GB0424188 A GB 0424188A GB 0424188 A GB0424188 A GB 0424188A GB 2405336 A GB2405336 A GB 2405336A
Authority
GB
United Kingdom
Prior art keywords
chemicals
injuries caused
cholinesterase inhibitors
prevent injuries
cholinesterase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0424188A
Other versions
GB0424188D0 (en
Inventor
John Ieni
Raymond Pratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of GB0424188D0 publication Critical patent/GB0424188D0/en
Publication of GB2405336A publication Critical patent/GB2405336A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catching Or Destruction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods for treating and preventing injuries caused by chemicals by administering to a patient a therapeutically effective amount of at least one cholinesterase inhibitor The chemicals can be, for example, agricultural compounds or chemical weapons. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof.

Description

GB 2405336 A continuation (74) Agent and/or Address for Service: Elkington
and Fife LLP Prospect House, 8 Pembroke Road, SEVENOAKS, Kent, TN13 1XR, United Kingdom
GB0424188A 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals Withdrawn GB2405336A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656002P 2002-05-01 2002-05-01
PCT/US2003/013575 WO2003092606A2 (en) 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals

Publications (2)

Publication Number Publication Date
GB0424188D0 GB0424188D0 (en) 2004-12-01
GB2405336A true GB2405336A (en) 2005-03-02

Family

ID=29401361

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0424188A Withdrawn GB2405336A (en) 2002-05-01 2003-05-01 Cholinesterase inhibitors to prevent injuries caused by chemicals

Country Status (3)

Country Link
AU (1) AU2003228796A1 (en)
GB (1) GB2405336A (en)
WO (1) WO2003092606A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2140868A1 (en) 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
PL1622569T3 (en) 2003-04-24 2016-06-30 Incyte Holdings Corp Aza spiro alkane derivatives as inhibitors of metallproteases
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AU2012200612B2 (en) * 2004-09-24 2014-11-20 The Government Of The United States, As Represented By The Secretary Of The Army Method of treating organophosphorus poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
AU2005289808B2 (en) * 2004-09-24 2011-11-03 The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense Method of treating organophosphorous poisoning
JP4872044B2 (en) * 2005-09-30 2012-02-08 財団法人ヒューマンサイエンス振興財団 Cardiac remodeling inhibitor and heart failure treatment
WO2008141081A1 (en) 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
DK3137168T3 (en) 2014-04-30 2022-03-21 Univ Columbia SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
TWI698436B (en) 2014-12-30 2020-07-11 美商佛瑪治療公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6114347A (en) * 1993-12-10 2000-09-05 Lts Lohmann Therapie-Systeme Gmbh Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6114347A (en) * 1993-12-10 2000-09-05 Lts Lohmann Therapie-Systeme Gmbh Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine

Also Published As

Publication number Publication date
WO2003092606A2 (en) 2003-11-13
GB0424188D0 (en) 2004-12-01
AU2003228796A8 (en) 2003-11-17
AU2003228796A1 (en) 2003-11-17
WO2003092606A3 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
GB2405336A (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
NO20020978L (en) Use of inhibitors of the renin-angiotensin system for the prevention of cardiovascular conditions
EP1480634A4 (en) Treating benign prostate hyperplasia with sarms
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2002010137A3 (en) Indazole derivatives as JNK inhibitors
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
AU7031500A (en) Therapeutic quinazoline compounds
MXPA05006359A (en) Disease treatment via antimicrobial peptide inhibitors.
WO2004052853A3 (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
PT1206444E (en) COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY
TW200503689A (en) Pharmaceutical compositions of atorvastatin
HUP9801022A2 (en) Use of aldose reductase inhibitor in preventing or reversing diabetic cardiomyopathy
TW200503690A (en) Pharmaceutical compositions of atorvastatin
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2001000197A3 (en) Methods of treating fungal infections with inhibitors of nad synthetase enzyme
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation
NO20035038D0 (en) Prevention of addiction to pain management
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2005041886A3 (en) Methods for generating or increasing revenues related to pain inhibitor commerce
PL369772A1 (en) Compounds that inhibit factor xa activity
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
WO2001055108A3 (en) Use of spl a2 inhibitors for the treatment of inflammation

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)